Complement C3 and C-reactive protein levels in patients with stable coronary artery disease

被引:60
|
作者
Ajjan, R [1 ]
Grant, PJ [1 ]
Futers, TS [1 ]
Brown, JM [1 ]
Cymbalista, CM [1 ]
Boothby, M [1 ]
Carter, AM [1 ]
机构
[1] Univ Leeds, Acad Unit Mol Vasc Med, LIGHT Labs, Leeds Inst Genet Hlth & Therapeut,Fac Med & Hlth, Leeds LS2 9JT, W Yorkshire, England
关键词
coronary artery disease; inflammation; C3; CRP; myocardial infarction;
D O I
10.1160/TH05-06-0384
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to determine whether complement C3 is an indicator of coronary artery disease (CAD). We measured plasma C3 and CRP levels in 278 patients undergoing coronary angiography for typical symptoms of CAD and 269 healthy age and sex matched controls. C3 levels were significantly higher in patients compared with controls (1.15 g/l and 0.92 g/l respectively; p<0.001). In the patient group, C3 levels correlated with BMI, fasting glucose, HbAIc,fibrinogen, CRP and HDL in both men and women CRP levels were also higher in patients compared with controls (1.14 mg/l and 0.86 mg/l respect lively; p=0.005) and correlated with markers of the metabolic syndrome. In a logistic regression model including C3, smoking, hypertension, cholesterol and diabetes, C3 was independently associated with CAD with an odds ratio of 3.20 for a I SD increase in C3 levels. In contrast, CRP was not independently associated with CAD in a similar regression analysis. In conclusion, both C3 and CRP plasma levels are elevated in patients with symptoms of CAD. However, C3 seems to be a better indicator of CAD than CRP in this study, suggesting that C3 could be an additional marker for risk stratification in atherosclerosis.
引用
收藏
页码:1048 / 1053
页数:6
相关论文
共 50 条
  • [31] PERCUTANEOUS CORONARY INTERVENTION CAUSES PROLONGED C-REACTIVE PROTEIN INCREASE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
    Mostowik, M.
    Siniarski, A.
    Poreba, M.
    Konduracka, E.
    Nessler, J.
    Gajos, G.
    ATHEROSCLEROSIS, 2014, 235 (02) : E138 - E139
  • [32] C-Reactive Protein, Uric Acid, and Coronary Artery Ectasia in Patients with Coronary Artery Disease
    Argan, Onur
    Bozyel, Serdar
    MEDICAL SCIENCE MONITOR, 2025, 31
  • [33] The association of complement C3 genotype with coronary artery disease, markers of the metabolic syndrome and C3 plasma levels
    Ajjan, RA
    Grant, PJ
    Futers, TS
    Brown, JM
    Carter, AM
    THROMBOSIS AND HAEMOSTASIS, 2006, 95 (02) : 393 - 394
  • [34] Atherosclerotic Lesion of the Vessels in Patients With Stable Coronary Artery Disease: Relations With Concentration of C-reactive Protein
    Panyugova, E. V.
    Aleksandrova, E. N.
    Nasonov, E. L.
    Karpov, U. A.
    KARDIOLOGIYA, 2009, 49 (04) : 40 - 45
  • [35] Prognostic value of plasma high-sensitivity C-reactive protein levels in Japanese patients with stable coronary artery disease
    Momiyama, Y.
    Kawaguchi, A.
    Kajiwara, I.
    Ohmori, R.
    Ohsuzu, F.
    Tsushima, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 281 - 281
  • [36] Variation in High-Sensitivity C-Reactive Protein Levels over 24 Hours in Patients with Stable Coronary Artery Disease
    Koc, Mevlut
    Karaarslan, Osman
    Abali, Gulcan
    Batur, Mustafa Kemal
    TEXAS HEART INSTITUTE JOURNAL, 2010, 37 (01) : 42 - 48
  • [37] C-Reactive Protein in Angiographically Documented Stable Coronary Disease
    Nezhad, M. J. Zibaee
    Ghanbari, P.
    Shahryari, B.
    Aghasadeghi, K.
    INTERNATIONAL CARDIOVASCULAR RESEARCH JOURNAL, 2009, 3 (02) : 97 - 101
  • [38] Elevation of high-sensitive C-reactive protein levels in patients with coronary artery disease.
    Meng, QH
    Luxton, G
    CLINICAL CHEMISTRY, 2004, 50 (06) : A4 - A5
  • [39] Plasma C-reactive protein concentration in patients with coronary artery disease and hypertension
    Dzielinska, Z
    Naruszewicz, M
    Nowicka, G
    Zielinski, T
    Prejbisz, A
    Demkow, M
    Kadziela, J
    Rynkun, D
    Januszewicz, A
    Ruzyllo, W
    JOURNAL OF HYPERTENSION, 2004, 22 : S103 - S103
  • [40] C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease
    Fichtlscherer, S
    Breuer, S
    Schächinger, V
    Dimmeler, S
    Zeiher, AM
    EUROPEAN HEART JOURNAL, 2004, 25 (16) : 1412 - 1418